Peptide Library / Detail
Dulaglutide
Half-life
Approximately ~120 hours (~5 days)
Delivery
Once-weekly subcutaneous injection (prefilled pen formats in clinical use; dose and device vary by study/protocol).
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Dulaglutide is a long-acting GLP-1 receptor agonist composed of two GLP-1 analog chains fused to an IgG4 Fc fragment. In research settings it’s used to study glucose homeostasis, gastric emptying, appetite regulation, and cardiometabolic outcomes.
Usage
Investigated for improving glycemic control, reducing cardiometabolic risk markers, and modeling weight/appetite pathways via incretin signaling.
Mechanism of Action
Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying, and reduce appetite through central and peripheral pathways.
Benefits(4)
- Improved fasting and postprandial glucose
- Reduced A1c in type 2 diabetes models
- Decreased appetite and body weight in study populations
- Potential cardiovascular risk-marker improvements
Side Effects(6)
- Nausea, vomiting, diarrhea, or constipation
- Abdominal pain or decreased appetite
- Injection-site reactions
- Rare: pancreatitis, gallbladder disease
- Hypoglycemia when combined with insulin or sulfonylureas
- Boxed warning (rodent): thyroid C-cell tumors; contraindicated with personal/family history of MTC or MEN2 in clinical use contexts